A new generation of multi-functional cancer immunotherapies October 2019Products, Clinical Indications and Scientific Overview Forward-Looking Statements 2 This presentation contains forward-looking statements about PDS

A new generation of multi-functional cancer immunotherapies October 2019Products, Clinical Indications

and Scientific Overview

Forward-Looking Statements 2 This presentation contains forward-looking statements about PDS

Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated preclinical and clinical drug development activities and timelines and market

opportunities. All statements other than statements of historical facts included in this presentation are forward-looking statements. The words "anticipates," "may," "can," "plans," "believes," "estimates," "expects," "projects," "intends,"

"likely," "will," "should," "to be," and any similar expressions or other words of similar meaning are intended to identify those assertions as forward-looking statements. These forward-looking statements involve substantial risks and

uncertainties that could cause actual results to differ materially from those anticipated.Factors that may cause actual results to differ materially from such forward-looking statements include those identified under the caption "Risk

Factors" in the documents filed with the Securities and Exchange Commission from time to time, including its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. You are cautioned not to place undue

reliance on these forward-looking statements, which speak only as of the date of this presentation. Except to the extent required by applicable law or regulation, PDS undertakes no obligation to update the forward-looking statements included

in this presentation to reflect subsequent events or circumstances.

3 Table of Contents Introduction to the Versamune -based immunotherapies Slide 3Versamune Products:

Clinical and commercialization strategy Slide 8PDS0101 product: Clinical trials, markets, immunology & efficacy Slide 10Versamune oncology pipeline - preclinical stage Slide 18PDS0102 for prostate cancer - overview, preliminary data

Slide 19PDS0103 for MUC-1 cancers - overview, preliminary data Slide 23PDS0104 for melanoma - overview, preliminary data Slide 25Versamune mechanism of action studies Slide 27Summary of mechanism Slide 53Intellectual property Slide

55Conclusions Slide 56

Versamune Overcomes key Limitations of Immunotherapy 4 Limitations of T-Cell Activators Cancer

vaccines have been unsuccessful in generating strong in-vivo killer (CD8+) T-cells necessary for therapeutic benefitAdjuvant technologies have been unsuccessful in facilitating antigen* processing and presentation to CD8+ T-cells therefore

resulting in sub-optimal therapeutic benefit The first truly multi-functional immunotherapeutic platformEngineered to promote efficient antigen uptake, processing and presentation to killer and helper T-cellsSuperior levels of in-vivo

tumor-specific killer T-cell inductionSuperior in-vivo induction of high quality/poly-functional T-cellsDemonstrated ability to break tumor immune toleranceSuperior safety and anti-tumor responses Solutions Provided by Versamune Antigen

- The unique protein associated with the cancer that is not expressed by normal healthy cells and which is recognized by the immune system

5 Introduction to the Versamune Platform Technology The proprietary Versamune platform technology

is based on structure-specific positively charged (cationic) and immune activating lipids that form spherical liposomal nanoparticles in aqueous media and are sized to mimic viruses Water-soluble & positively charged head-groupcoats the

particle surface Water-insolubleFatty acids/hydrocarbon chains

Multi-Functional Versamune Platform Overcomes key Limitations of Immunotherapy 6 Engineered to

promote in-vivo induction of tumor-recognizing and attacking killer (CD8+) T-cells* Trains killer T-cells to recognize & attack cancer Activates powerful T-cells to attack cancer cells Makes tumors more susceptible to T-cell

attack Positively charged nano-particles engineered to access critical MHC Class I pathway Activates stimulation of type I interferon (IFN) genes within lymph nodes Significantly increases ratio of killer T-cells to immune-suppressive

regulatory T-cells Induces memory immune response Body generates tumor-attacking T-cells for extended period after treatment Potent poly-functional T-cells De-camouflaged tumor Robust / lasting effect 1 2 3 4 *Mechanism of Action:

Journal of Immunology, Vol. 202, Issue 1215 June 2019

Unique Versamune -Based Immunotherapies Present Advantages in Efficacy, Manufacturing, and

Administration 7 Vials Versamune Formulations By Electron Microscopy Vial of Versamune Vial of Tumor antigens Versamune Proprietary tumor antigens Mixed Bedside

8 Versamune Immunotherapies: Clinical Development Strategy Checkpoint inhibitors have shown

confirmed clinical efficacy and have demonstrated clinical benefit in late stage cancer.Checkpoint inhibitors work by blocking one of the cancer's key immunological defense mechanisms, and are reported to only work in patients whose immune

systems are already generating tumor attacking CD8 killer T-cells pre-treatmentUsing various tumor-specific proteins (antigens), Versamune has demonstrated the ability to generate large numbers of CD8 killer T-cells that effectively

recognize and kill the antigen-expressing cancer cells in preclinical and in human clinical studiesBy combining the Versamune -based immunotherapies with checkpoint inhibitors and other standard of care modalities, PDS plans to generate a new

generation of effective treatments for advanced cancer The immunotherapies are being developed as combination therapies to exploit the demonstrated synergies between the Versamune technology and checkpoint inhibitors *L. V. Wood et al et

al, Oncoimmunology, 2016, Vol. 5 (8)**S. Gandhapudi et al, Journal of Immunology, 2019 (202), 1215

Synergy of Versamune + Tumor Antigen and Checkpoint Inhibitor: Demonstrated in Aggressive &

Difficult-to Treat B16 Melanoma Model 9 Versamune + TRP2 (PDS0104) injection demonstrates strong synergy in combination with a checkpoint inhibitor in B16 melanoma - Provides significantly prolonged survival over checkpoint inhibitor

therapy** Treatment started UntreatedAnti PD-1 checkpoint inhibitor (CPI)Versamune + TRP2 AntigenCPI + Versamune + TRP2 No survivors by Day 18CPI-treated ineffective dueto absence of tumor infiltrating T-cells *Vasievich et al,

Molecular Pharmaceutics 2012, 6, 9(2) 261-8**S. Gandhapudi et al, Journal of Immunology, 2019 (202), 1215 Percentage of CD4+ and CD8+ among all cells in the tumor mass 75nmol TRP2+ Versamune 75nmol TRP2 Versamune induces

TRP2-specificCD4+ (helper) and CD8+ (killer) T-cells& infiltration into the B16 tumor 7 daysafter a subcutaneous injection*

10 PDS0101 Immunotherapy for Advanced HPV-Associated Cancers PDS0101 is based on two key

components:Proprietary mixture of six HPV16 E6 and E7 multi-epitope peptides designed to address over 90% of the population. HPV16 causes the vast majority of the HPV associated cancers. In a human clinical trial the PDS has demonstrated that

the proprietary antigens are effectively recognized by the immune systems of HPV-infected patients. Treatment led to strong HPV-specific killer T-cell responses and clinical benefit. The proprietary Versamune platform technology which has

demonstrated exceptional ability to train the killer (CD8+) T-cells of the immune system to recognize the specific tumor antigens included in the formulation, and to arm the T-cells with potent ability to specifically attack and kill the

cancer cells expressing the tumor antigen** *L. V. Wood et al et al, Oncoimmunology, 2016, Vol. 5 (8)**S. Gandhapudi et al, Journal of Immunology, 2019 (202), 1215

PDS0101 Phase 2 Combination Trials with Leaders in Immuno-Oncology 11 11 PDS

Product Indication Partner Added Combination Product Study Size PDS0101(HPV-Cancer) Head & neck cancer First line treatment Recurrent/metastatic KEYTRUDA FDA-approved 96 subjects20 US sites Advanced HPV cancers

Confidential Large Pharma Two NovelImmunotherapies (Superior results in phase 1 studies) 30 subjects1 US site (NCI) Cervical cancerStage IIb-IVa To be announced Chemo-radiotherapy (Standard of care) 33 subjects1 US site * These

clinical studies are expected to be initiated with current funding All clinical trials to be initiated in Q1 2020Interim data expected within 18 months of start

HPV-Associated Cancer Annual Incidences - United States* 12 12 HPV experts project that current HPV

preventive vaccines will have little impact on HPV-related cancer incidences over next twenty-plus years** * CDC Data Brief, August 2018 - based on data collected 2011-2015** 2016 Report by Dr. Laurie Markowitz, Epidemiologist, U.S. Centers

for Disease Control and Prevention Female Male 100% = 24,391 100% = 18,280 Annual Incidence~43,000 HPV-associated cancersTrial: PDS0101 + 2 immunotherapiesCervical cancerMost common HPV-cancer in women Incidence steadyTrial: PDS0101 +

Chemoradiotherapy (SOC)Oropharyngeal (head & neck) cancers Most common HPV-cancer in menIncidence increasingTrial: PDS0101 + Keytruda (SOC)

13 PDS0101 Proprietary formulation: Mixture of Peptide Micelles with Versamune Promotes Superior CD8+

T-Cell Response Comparison of Micellar vs. Traditional Encapsulation Methods - IFN- ELISPOT Shows Superior Potency of the PDS Micellar Approach* DOPC and DOTMA (Lipids covered under Versamune -class) formulated using a weakly immunogenic

HPV antigen: CD8+ T-cell response of DOTMA and DOEPC vastly superior to the clinical-stage adjuvant Montanide (ISA Pharma - HPV competitor) The micellar peptides without Versamune generate a very weak CD8+ T-cell response even less than seen

with Montanide IFN- Spots per 106 Splenocytes *Patent covers compositions of micellar antigens and cationic lipidsUS patent prosecution on-going; Patents issued in EU and JP

Versamune : Superior Antigen Processing & Presentation Promotes Superior Quantity & Quality

Tumor-Attacking Killer T-Cells In-Vivo 14 500 1,000 1,500 2,000 PDS0101* Cytokine/E7* Electroporation# Live Vector Vaccine## # of HPV-Recognizing T-CellsIFN- Spot Forming Cells/1X106 Spleen cells Versamune (R-DOTAP)

induces approx. 10-fold higher number of potent/polyfunctional T-cells vs. competition *J. Immunology, 2019 (202), 1215Studies in TC-1 tumor model with other immunotherapies reported in: #Vaccine 2009, January 14, 27 (3): 431;##Journal for

Immunotherapy of Cancer, 2013 (1) 15 Polyfunctional/mostpotent killer T-cells (4-Adjuvant Combination) (Positive Control) 40.78% 18.9% 16.55% 40.5%

PDS0101: Promotes Superior Ability to Eliminate HPV-Positive TC-1 Tumors & Generates Sustained

(Memory) T-Cell Response 15 In vivo induction of superior quantity & quality of tumor-specific CD4+ and CD8+ T-cells result in complete regression & effective T-cell memory after a single dose* *J. Immunology, 2019 (202),

1215**Studies in TC-1 tumor model with other immunotherapies reported in: Vaccine 2009, January 14, 27 (3): 431; Science Translational Medicine 2016, 13 April, Vol 8 Issue 334; Vaccine 2009, August 3, 27 (33): 5706 Single treatment

dose 50 55 60 80 Inject TC-1 Tumor Cells Top competitors such as live vectorsTLR agonist adjuvants, electroporationonly slow down TC-1 tumor growth (delay death)**

Human clinical results: Phase 1/2a Dose Escalating Study Shows Potent HPV16 CD8+ T-Cell Induction by

Granzyme-b ELISPOT Clinical Study DesignOpen-label studyCervical Intraepithelial Neo-plasia (CIN) & high-risk HPV infection3 cohorts, each 3-6 subjectsEvaluated safety, tolerability & T-cell immunogenicity 14x 24x Total T-Cells

26x Over 20-Fold Increase in HPV-Specific CD8+ T-Cell ResponsesVersus Pre-Treatment Levels at Recommended Clinical Doses 16 Days Dosage Unlike PDS0101, no T-cell activating technology or immunotherapy has demonstrated the ability to

induce in-vivo in humans, quantifiable amounts of granzyme-b inducing antigen-specific CD8+ T-cells in circulating blood

PDS0101: Phase 1 Follow-up Data Supports Observed Strong Killer T-Cell Induction Causing Clearance of

CIN Lesions in 60% of Evaluable Patients 17 PDS0101 was immunologically active at all three doses resulting in 5 to 73-fold increase in circulating HPV disease-attacking T-cells in 10/12 subjectsClearance of the CIN (lesion regression) was

observed in 60% of evaluable patients across the three tested doses, as early as 1-3 months after treatment in some patients Dose Cohort Evaluable Patients* Clearance of Lesions 12 Months Post Treatment** N = N = % of

Evaluable 1mg 3 of 3 2 67% 3mg 2 of 3 1 50% 10mg 5 of 6 3 60% Total 10 6 60% *Two of twelve patients were not evaluable: one patient, who demonstrated a strong immune response, was lost to follow up and another received LEEP

excision therapy (standard of care) **Two of ten evaluable patients who had clearance of CIN by cytology were not considered as clinical responders: one patient regressed from CIN to atypical squamous cells of undetermined

significance (ASCUS) with detectable virus, and the other showed consistent disease elimination by cytology, but showed residual disease by colposcopy

Developing Broad Product Pipeline with Leaders in

I-O 18 Product Indication Partner Combination Status PDS0102(TARP) Prostate and breast cancers Checkpoint Inhibitor Preclinical studies ongoing PDS0103(MUC-1) Ovarian, colorectal, lung, breast cancers TBD Checkpoint

Inhibitor Preclinical studies ongoing PDS0104(Melanoma) Melanoma TBD Checkpoint Inhibitor Preclinical studies ongoing

19 PDS0102 Immunotherapy for Prostate Cancer PDS0102 is based on two key components:The novel and

proprietary TARP protein, a tumor antigen identified by the National Cancer Institute (NCI) that is expressed in about 90% of prostate cancers at all stages of the disease. In a human clinical trial the NCI demonstrated that the antigen was

effectively recognized by the immune system in prostate cancer patients with PSA biochemical recurrence leading to a reduction in tumor growth rate*The proprietary Versamune platform technology which has demonstrated exceptional ability to

train the killer (CD8+) T-cells of the immune system to recognize the specific tumor antigens included in the formulation, and to arm the T-cells with potent ability to specifically attack and kill the cancer cells expressing the tumor

antigen** *L. V. Wood et al et al, Oncoimmunology, 2016, Vol. 5 (8)**S. Gandhapudi et al, Journal of Immunology, 2019 (202), 1215

20 Clinical Development of PDS0102: PDS Biotechnology has signed a collaborative research and

development agreement (CRADA 03039) with the National Cancer Institute to co-develop PDS0102 (NCI-patented TARP cancer antigen with R-DOTAP):Checkpoint inhibitors have shown confirmed clinical activity and have demonstrated strong potential

in on-going prostate cancer trials.In on going preclinical studies R-DOTAP, has demonstrated the ability to significantly enhance the immune system's ability to generate TARP-recognizing killer T-cellsProstate cancer patients treated with a

TARP-based immunotherapy (no R-DOTAP) showed generation of TARP recognizing T-cells and reduction in tumor growth rate* *L. V. Wood et al et al, Oncoimmunology, 2016, Vol. 5 (8)

21 PDS0102: R-DOTAP May Provide Superior In-Vivo Ability to Generate Significantly Enhanced

Anti-TARP Killer T-Cell Response* *Ongoing preclinical development at PDS Biotechnology CFA +TARP (1-20) R-DOTAP +TARP (1-20) Number of TARP-Specific T-cells(Interferon- spot forming cells per million splenocytes) PRE-CLINICAL

OPTIMIZATION STUDIES: TARP-Specific T-cell Induction after 2 injections of R-DOTAP + TARP (1-20) IFN- ELISPOT Study Range of observed T-cell responsesWith Versamune + TARP(1-20) 100 spots/million cellsStrong T-cell response level CFA

- Complete Freund's Adjuvant a highly potent immune activator not used in humans due to potentially lethal toxicity

22 Formulation Optimization GMP ManufacturingPeptide, R-DOTAP First Patient DosedQ4 2020/Q1

2021 Late Q1, 2020 Q3, 2020 Planned PDS0102 Clinical Development Timeline* *Assumes additional funding to support development.

23 PDS0103 Immunotherapy for Breast, Colon, Lung & Ovarian Cancers PDS0103 is based on two key

components:The novel and proprietary peptide agonist epitopes of the MUC-1 oncoprotein, developed and patented by the National Cancer Institute (NCI). The novel analogs provide significantly higher immunogenicity and also induce significantly

higher avidity T-cells compared to native MUC-1. These antigens have been licensed by PDS from the NCI for the four indications above.*The proprietary Versamune platform technology which has demonstrated exceptional ability to train the

killer (CD8+) T-cells of the immune system to recognize the specific tumor antigens included in the formulation, and to arm the T-cells with potent ability to specifically attack and kill the cancer cells expressing the tumor

antigen** *Jochems et al, 2014 Cancer Immunol Immunother 63, 161 -174**S. Gandhapudi et al, Journal of Immunology, 2019 (202), 1215

24 PDS0103: R-DOTAP May Provide Superior In-Vivo Ability to Generate Significantly Enhanced Anti-MUC1

Killer T-Cell Response* *Ongoing preclinical development at PDS Biotechnology**P < 0.05 R-DOTAP + MUC1 Antigens (V1A, V2A, C1A, C2A)Sucrose + MUC1 Antigens (V1A, V2A, C1A, C2A) Montanide - LTR agonist emulsion clinical-stage